LNA043 / Novartis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LNA043 / Novartis
ONWARDS, NCT04864392 / 2020-004897-22: Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

Active, not recruiting
2
583
Europe, Canada, Japan, US, RoW
LNA043 Dosing Regimen A, LNA043, LNA043 Dosing Regimen B, LNA043 Dosing Regimen C, LNA043 Dosing Regimen D, Placebo
Novartis Pharmaceuticals
Osteoarthritis
09/24
05/25
NCT04814368 / 2020-003631-21: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Terminated
2
23
Europe, US, RoW
canakinumab, ACZ885, LNA043, Placebo to canakinumab
Novartis Pharmaceuticals
Knee Osteoarthritis
06/24
06/24

Download Options